These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23414664)

  • 1. Evaluation of weight-based dosing of unfractionated heparin in obese children.
    Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL
    J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
    Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
    Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin dosing in obese pediatric patients in the cardiac catheterization laboratory.
    Moffett BS; Teruya J; Petit C
    Ann Pharmacother; 2011 Jul; 45(7-8):876-80. PubMed ID: 21775696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome.
    Joncas SX; Poirier P; Ardilouze JL; Carrier N; Fayad T; Farand P
    Obesity (Silver Spring); 2013 Sep; 21(9):1753-8. PubMed ID: 23404940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
    Myzienski AE; Lutz MF; Smythe MA
    Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.
    Bauer SR; Ou NN; Dreesman BJ; Armon JJ; Anderson JA; Cha SS; Oyen LJ
    Mayo Clin Proc; 2009 Dec; 84(12):1073-8. PubMed ID: 19955244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
    Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
    Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: a retrospective cohort study.
    Ryerson LM; Bauman ME; Kuhle S; Bruce AA; Massicotte MP
    Pediatr Crit Care Med; 2014 Oct; 15(8):e340-6. PubMed ID: 24901804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
    Clark NP; Delate T; Cleary SJ; Witt DM
    Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients.
    Isherwood M; Murphy ML; Bingham AL; Siemianowski LA; Hunter K; Hollands JM
    J Thromb Thrombolysis; 2017 May; 43(4):476-483. PubMed ID: 28070821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients.
    Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M
    J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone.
    Rosborough TK
    Pharmacotherapy; 1998; 18(6):1217-23. PubMed ID: 9855319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.